Introduction {#s0005}
============

Rare circulating tumor cells (CTCs) are some special cancer cells which detach from the primary solid tumor and/or metastasis then circulate in peripheral blood [@bb0005]. CTCs have been considered as the probable cause of fatal metastatic disease [@bb0005], [@bb0010], [@bb0015]. A better understanding of the biology of CTCs may provide a potential alternative access to solid tumor and further the study of tumor metastasis and disease progression (regarded as a "liquid biopsy" for epithelial cancers) [@bb0020]. However, the acquisition and analysis of CTCs are still one of the technically challenges because these cells are extremely rare (a few to hundreds cells per milliliter) and mixed with a large number of hematologic cells (10^9^ cells per milliliter) [@bb0025], [@bb0030]. Over the past decade, some technologies have been developed to detect CTCs, including flow cytometry [@bb0035] and size-based separation [@bb0040], [@bb0045]. The immunomagnetic separation-based CellSearch™ Assay is the only FDA-approved CTC diagnostic technology for metastatic breast, prostate and colorectal cancers. Consequently, metastatic breast cancer patients with 5 or more CTCs counts (enumerated by CellSearch-Veridex) in 7.5 mL blood before treatments may suffer poor progression-free survival and overall survival [@bb0025]. However, due to its low capture yield and high cost of isolating CTCs, monitoring CTCs from gastrointestinal cancer patients to guide therapeutic choices has not been established [@bb0050], [@bb0055].

Previously, we have reported a high efficient CTCs detection assay using a horizontally packed TiO~2~ nanofibers [@bb0060]. The capture of CTCs by this method mainly depends on the enhanced local topographic interactions [@bb0065], [@bb0070] between nano-components on cancer cell membrane (e.g., microvilli and filopodia) and the antibody (anti-EpCAM [@bb0075]) coated nanofibers, which improves the CTCs capture efficiency. Due to the complex process control and special equipment for preparing these special nanostructures, this method have been limited for high throughput fabrication. It\'s urgent to develop a new device that is worth popularizing in clinical practice for its simple manufacture, low cost and convenient use.

Herein, based on our previous publications, we utilize our recent CTC detection device made of hydroxyapatite/chitosan (HA/CTS), optimized from our previous works (TiO~2~ nanoparticles [@bb0080] and HA-CTS nanofilms [@bb0085]) for rare cancer cells isolation and enumeration in clinical use. Results showed that capture yields of more than 80% can be achieved through the use of our substrate (new version of HA-CTSNF). Given the high sensitivity and specificity of the new version of HA-CTSNF substrate, we validated the ability of isolation and enumeration of CTCs in totally 32 localized and metastatic gastrointestinal cancer patients and tested its potential utility in monitoring response to anti-cancer therapy.

Materials and Methods {#s0010}
=====================

Materials {#s0015}
---------

Hydroxyapatite (HA) in powder form was purchased from Sigma Aldrich (St Louis, MO), chitosan (CTS) was obtained from Haisheng Co., Ltd (Qingdao, China), 4-Maleimidobutyric acid N-hydrosuccinimide (≥ 98% GMBS), 3-mercaptopropyl trimethoxysilane (95% MTPMS), paraformaldehyde (PFA), streptavidin (1 mg mL^− 1^ SA), biotinylated anti-human EpCAM/TROP1 antibody (Goat IgG) were supplied by R&D systems (Minneapolis, MN). Anti-human CD45-FITC (Ms IgG1, clone H130) and anti-cytokeratin-PE (CAM5.2, conjugated with phycoerythrin) were purchased from BD Biosciences (San Jose, CA). Triton X-100 and 4′, 6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from Sigma-Aldrich (St Louis, MO). Phosphate-Buffered Saline (PBS 1X, 0.0067 M PO4^3 −^), RPMI-1640 growth medium, dulbecco\'s modified eagle medium (DMEM), Tween-20, fetal bovine serum (FBS) and 0.25% Trypsin-EDTA (Gibco, 1X) were supplied by Invitrogen (Carlsbad, CA). Colorectal cancer cell line (HCT116), gastric cancer cell line (MGC803), cervical cancer cell line (HeLa) and chronic myelogenous leukaemia cell line (K562) were harvested from Hubei Key Laboratory of Tumor Biological Behaviors.

### Blood samples {#s0025}

Whole blood samples from healthy donors were obtained from Department of Clinical Laboratory, Zhongnan Hospital of Wuhan University according to a protocol by the Institutional Review Board (IRB) and cancer patients\' blood samples were obtained from Department of Oncology, Zhongnan Hospital of Wuhan University under a separate IRB-approved protocol. All blood samples were collected into Anticoagulant tubes (EDTAK2, 2 ml, violet cap) and processed within 12 h.

### Fabrication of HA-CTS nanofilm substrate {#s0030}

According to our previously established method[@bb0085], HA-CTS nanofilm (HA-CTSNF) was prepared as below. Firstly, the glass substrate was boiled in Piranha solution (3:1 (v/v) H~2~SO~4~/H~2~O~2~) at 100 °C for 1 h, washed several times with deionized water, then treated by oxygen plasma treatment (PDC-32G, Harrick Plasma, USA) for 2 min, and dried with nitrogen gas. A chitosan aqueous solution of 2 wt% was prepared by dissolving chitosan powder into distilled water containing 2% acetic acid and then 5 wt% nano-hydroxyapatite (HA) powder was added slowly. The mixed solution was blended by magnetic stirrer for 12 h and then uniformly coated on the clean glass by using a photoresist spinner (10000 r/h, 60 seconds). In the baking process the coated solution was heated on bake table for 1 h. Following the baking process the HA-CTS nanofilm substrate was soaked in 10 wt% NaOH solution for 10 h. Finally, the substrate was washed with DI water, dried and ready for chemical modification. The morphology of the HA-CTS nanofilm substrate was observed by Field Emission Scanning Electron Microscopy (SEM, 6700 F, JEOL, Japan). Compared to our previous works ([Table 1](#t0005){ref-type="table"}), the new version of HA-CTSNF has a larger surface area, higher transmittance, and equally high capture efficiency. It may increase the "loading capacity" and enable the anti-EpCAM modified HA-CTSNF to directly monitor the captured cancer cells.Table 1Comparison of the Fabrication Specifications Between the Previous Reported Methods and the New Version of the HA-CTSNFTiO~2~ NanoparticlesHA-CTSNFNew Version of HA-CTSNFPhotoresist spinner parameter-6000 r/h, 60 s10000 r/h, 60 sNanosubstrate roughness100-140 nm170-250 nm120-170 nmNanosubstrate area1 cm × 1 cm1 cm × 1 cm2 cm × 2 cm

### Surface modification with antibody {#s0035}

Surface modification procedure for the HA-CTSNF was reported earlier [@bb0090]. The HA-CTSNF substrate was modified with 4% (v/v) 3-mercaptopropyl trimethoxysilane (MPTMS) in ethanol at room temperature for 1 h [@bb0095]. Then, the substrate was treated with the coupling agent N-y-maleimidobutyryloxy succinimide ester (GMBS, 0.25 mM) for 1 h make for GBMS attachment to the substrate. Next, the substrate was treated with streptavidin (SA) at room temperature for 45 min, resulting in immobilization onto GMBS, and washed with 1 x PBS to remove excess SA before immersed in biontinylated anti-EpCAM solution (10 μg mL^− 1^ in PBS) for 60 min (RT).

### Cell capture and identification {#s0040}

1 mL cell suspension (i.e., HCT116, MGC803, HeLa and K562, 10^5^ cells mL^− 1^) was introduced onto the new version of HA-CTSNF substrate and incubated for 1 h (37°C and 5% CO^2^). Then, the chip was rinsed with PBS for 5 times. The captured cells on the chip were fixed with 4% paraformaldehyde (PFA) in PBS for 10 min. Then, the chip was loaded with 0.2% Triton X-100 in PBS and incubated for 10 min in order to improve the permeability of the cell and to allow for intracellular staining, 40 ul blocking solution (2% donkey serum in PBS/0.2% triton X-100) was added onto the chip and incubated for 30 min at room temperature, followed by staining with PE-labeled anti-CK and FITC-labeled anti-CD45 overnight. 4′, 6-diamidino-2-phenylindole dihydrochloride (DAPI, 0.33 μg mL^− 1^ in DI water) was used for staining nuclear for 10 min. Finally, detecting and counting of targeted cells using the fluorescence microscope (IX81, Olympus, Tokyo, Japan). Captured CTCs on chip were photographed by using IPP software (Media Cybernetics Inc., Silver Spring, MD).

### Cell capture from cancer patient blood samples {#s0045}

The circulating tumor cells from cancer patient were captured according to the procedure described below. About 4.0 mL patient peripheral blood sample was introduced onto our chip and captured for 1 h. After rinsing, followed by staining of anti-CK, anti-CD45 and DAPI, the specifically captured cancer cells were identified and counted on the substrates directly.

Results and Discussion {#s0020}
======================

The cancer cells capture principle of the HA-CTSNF substrate was illustrated in [Figure 1](#f0005){ref-type="fig"}. The improved HA-CTSNF substrate (New version of HA-CTSNF) was prepared by HA/CTS composites ([Figure 2](#f0010){ref-type="fig"}*A*, see details inMaterials and Methods). A layer of nanostructured film was fabricated onto a slide glass ([Figure 2](#f0010){ref-type="fig"}*B*). The roughness of the nanostructured substrates were controlled by changing the HA:CTS ratio. First, in order to demonstrate the surface roughness of nanostructured film impacts the capture yields, the biotin-HA-CTSNF substrate were prepared before cell capture ([Figure 2](#f0010){ref-type="fig"}*C*), and two EpCAM-positive cancer cell lines (HCT116, MGC803) were chosen and spiked into the Dulbecco\'s Modified Eagle\'s Medium (DMEM) at a concentration of 10^5^ mL^− 1^, then, these spiked cells were captured by anti-EpCAM-grafted substrates which has been prepared with different surface roughness (ranging from 20 to 280 nm). For comparison, two EpCAM-negative cancer cell lines (K562 and HeLa) were chosen for specific cell capture comparison experiments. As shown in [Figure 2](#f0010){ref-type="fig"}*D*, when the roughness of the substrates was around 150 nm, maximal cell capture yields were achieved for HCT116 cell line (approximately 81%) and MGC803 cell line (approximately 64%) while minor changes were observed for EpCAM-negative cells. These results revealed that the effect of roughness on the cell capture yields can be attributed to the local topographic interactions between nano-substrate and cancer cells.Figure 1Schematic of cancer cells capture principle of the HA-CTSNF substrate. Capture efficiency was improved by combining cell-capture-agent and cancer cell preferred nano-scaled topography of substrate.Figure 2(A) Schematic procedure for the fabrication of the nanostructured film. (B) Scanning electron microscopy (SEM) image of HA-CTSNF substrate. (C) Grafting of biotinylated epithelial-cell adhesion-molecule antibody (anti-EpCAM) onto HA-CTSNF substrate. The cell capture yields of the HA-CTSNF substrate with (D) different surface roughness of nanostructured film ranging from 20 to 280 nm and (E) at different incubation time (with incubation time of 15, 30, 45, 60 and 90 min). (F) Capture efficiencies of four different cell lines at the optimal cell capture conditions. (G) Comparison of capture efficiency of new version of HA-CTSNF with two different controls: (i) HA-CTSNF, (ii) TiO~2~ nanoparticles. Error bars show standard deviations (n = 3).

To determine the optimum incubation time for efficient cell capture, we performed experiment about incubation times by using the optimal substrate modified with anti-EpCAM as studied above. Two EpCAM-positive cancer cell lines (HCT116 and BGC803) and two EpCAM-negative cancer cell lines (K562 and Hela) were examined. The cell capture yields with different incubation time were shown in [Figure 2](#f0010){ref-type="fig"}*E*. For the EpCAM-positive cell line, the recovery yields of cell capture increased with increasing incubation time and significant changes had been observed, and the maximal recovery yields achieved saturation at an incubation of 60 min or longer. There was several times difference between the maximal recovery yields and the minimal recovery yields in our test, leading us to ascertain 60 min to be the minimum time for optimal capture.

Finally, we tested these four cell lines on the new version of HA-CTSNF under the optimal cell capture conditions, showed a high capture efficiency of 72% to 84% with EpCAM-positive cell lines ([Figure 2](#f0010){ref-type="fig"}*F*). New version of HA-CTSNF exhibited capture efficiency equal to that of our previous works when we compare the capture performance of new version of HA-CTSNF with HA-CTSNF and TiO~2~ nanoparticles ([Figure 2](#f0010){ref-type="fig"}*G*).

During the clinical utility of our platform for rare cancer cells capture from cancer patient peripheral blood samples, we evaluated the relationship performance between serial CTCs changes and the changes of tumor volume/serum tumor marker (i.e. CEA, CA19-9) in gastrointestinal cancer patients who have received anti-cancer treatments. Patients were followed up after discharge by physical examination, routine blood tests, serum tumor marker tests, and computed tomograms (CT scans) according to standard clinical practice. In the patient information table ([Table 2](#t0010){ref-type="table"}), CTC numbers were calculated before and 10--18 weeks after the treatment initiation. Medians and ranges were calculated on patients\' age and their serum CA19-9 and CEA concentrations. The frequencies and percentages were calculated for the patients\' clinical status. About 4.0 mL peripheral blood samples were introduced onto our substrate for cell capture, at the same time, 5 healthy donors\' epithelia blood samples were tested as control. Specifically captured CTCs (CK +/CD45 −/DAPI +, 10 μm \< cell sizes \< 30 μm) were identified f[r]{.ul}om WBCs (CK −/CD45 +/DAPI +, sizes \< 15 μm) using fluorescence microscopy [@bb0100], [@bb0105] ([Figure 3](#f0015){ref-type="fig"}*A*). CTC enumeration results obtained from 5 healthy donors and 32 cancer patients before treatment (12 gastric cancer patients and 20 colorectal cancer patients) were showed in [Figure 3](#f0015){ref-type="fig"}*B*. Cell counts of cancer patients ranging from 3 to 162 per 4.0 mL that were significantly higher than cells counts of healthy donors (0-5 CTCs/4 mL). The CTCs changes corresponded with tumor size ([Figure 3](#f0015){ref-type="fig"}, *C--D*), while the changes in CTCs did not always keep consistent in serum tumor marker ([Figure 3](#f0015){ref-type="fig"}, *E--F*), as a common phenomenon reported in early study (serum tumor marker flare after starting chemo). The results showed that enumeration of CTCs in cancer patients may predict clinical response to anti-cancer treatment. In general, these data demonstrated that our platform performed considerable capture efficiency and allowed for monitoring CTCs to evaluate the clinical treatment response and guide therapeutic choices.Figure 3(A) CTCs isolated from a colorectal cancer patient. Three-color immunocytochemistry method based on FITC-labeled anti-CD45, PE-labeled anti-CK, and DAPI nuclear staining was applied to identify and enumerate CTCs from non-specifically trapped WBCs. (B) CTC enumeration results obtained from healthy donors and cancer patients. Numerical analysis of 4 patients showing the number of CTCs (red), concentration of serum CA19-9, CEA and tumor size (black) measured as the unidimensional sum of all significant tumor sites on a CT scan. Imaging studies were assessed by a single reference radiologist (Haibin Song), who graded responses according to Response Evaluation Criteria in Solid Tumors (RECIST). Type of treatment and duration are noted for each case. Patients with diagnoses and specific therapies shown are (C) patient 6, gastric, SOX: S-1 plus Oxaliplatin, (D) patient 22, colorectal, FOLFOX 6: Oxaliplatin, 5-FU and leucovorin, (E) Patient 7: gastric, SOX, f) Patient 19, colorectal, FOLFOX 6.Table 2Clinicopathologic Characteristics and CTC Numbers of PatientsCancer SpeciesAge\
Median (Range)CTC/4 ml\
Median (Range)Serum CA19-9\
\[U/ml\]\
Median (Range)Serum CEA\
\[ng/ml\]\
Median (Range)Clinical StatusHealthy control (n = 5)25 (22-29)2.2 (0-5)\-\--Gastric cancer (n = 12)58.2 (39-75)35.75 (3-96)121.8 (2.69-\>1000)4.55 (0.74-35.5)I: 0 (0%)\
II: 2 (16.67%)\
III: 6 (50%)\
IV: 4 (33.33%)Colon cancer (n = 20)59.1 (38-80)47.55 (4-162)30.3 (2-304.7)8.24 (0.49-39.72)I: (10%)\
II: 7 (35%)\
III: 7 (35%)\
IV: 4 (20%)

Longitudinal monitoring of individual patients during the therapeutic process also showed a close correlation between CTC quantity and clinical response. We serially monitored CTCs in patient 9 with gastric cancer receiving SOX regimens (S-1 plus Oxaliplatin) and total gastrectomy. As result shown in [Figure 4](#f0020){ref-type="fig"} that declines in CTC number paralleled effective therapeutic interventions. With clinical benefit, CTC number of this patient rapidly decreased while serum CA19-9 concentrations also declined gradually, at the same time, the tumor size and lymph node sizes reduced obviously; irregularly thickening of gastric body near by the pancreas was disappeared and could be separated from mass tissue as shown in computed tomography image ([Figure 4](#f0020){ref-type="fig"}*A*). Another phenomenon could be observed that a temporally increment in CTC number during and after total gastrectomy and followed by a drop. This result may indicate that surgical operation increase the chance of cancer cells shed from solid tumor into the circulation. Above all our study showed that the capture efficiency of HA-CTSNF substrate is reliable and capable of longitudinal monitoring of cancer and this approach may have early diagnostic potential. A prospective trial would be needed to explore its predictive value.Figure 4Serial Changes of CTCs in cancer patient. (A) Computed tomography (CT) images in three different stages, i) before treatment, ii) after chemo and iii) after dissection. (B) Serial CTCs and serum CA19-9 changes of patient 9 are plotted. Type of treatment and duration are noted: Sox: S-1 plus Oxaliplatin, OPS: total gastrectomy.

In conclusion, CTCs isolation based on our platform allowed the longitudinal enumeration of cancer cells from cancer patients with high capture yield. Regarding the ability of monitoring CTCs from patient who are receiving clinical therapy, we expect this method is of application potential for treatment responses monitor, patient prognosis indication and cancer-related biological studies.
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